This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Lupus Foundation Of America Applauds Congress For Passing The Consolidated And Further Continuing Appropriations Act

WASHINGTON, March 21, 2013 /PRNewswire-USNewswire/ -- Sandra C. Raymond, President and Chief Executive Officer of the Lupus Foundation of America has issued the following statement regarding the passage today of legislation that funds federal government operations through the end of the fiscal year:

(Logo: )

"The  Lupus Foundation of America applauds Congress for funding vital lupus research and education programs by passing The Consolidated and Further Continuing Appropriations Act (H.R. 933), which funds federal government operations until September 30, 2013. 

"The Act provides funding for several important lupus initiatives advocated by the Lupus Foundation of America, such as:  
  • a $71 million increase for the National Institutes of Health (NIH) above the FY 2012 funding level of approximately $30.9 billion;
  • $4.4 million for the National Lupus Patient Registry (the lupus epidemiology project) at the Centers for Disease Control and Prevention (CDC);
  • $50 million for the Peer Reviewed Medical Research Program (PRMRP) at the Department of Defense, of which lupus is one of the diseases eligible for funding; and,
  • $1 million for The Lupus Initiative at the U.S. Department of Health and Human Services (HHS) Office of Minority Health (OMH).

"Federal funding for lupus research and education programs are important to helping solve the cruel mystery of lupus.  This bill will ensure that basic, clinical and translational research efforts on lupus will continue uninterrupted, including efforts to better understand the impact of lupus and provide a more accurate measure of the number of people living with lupus in the United States.  Funding also will help our nation's healthcare providers improve lupus diagnosis, treatment and disease management. 

"While the legislation provides funding for lupus programs across the federal government, many federal programs are still subject to the across-the-board cuts required by the sequester.  The NIH, CDC and OMH programs are subject to a 5 percent cut, and the PRMRP is subject to a 7.8 percent cut.  Even with the increases, after the sequester is applied the NIH will be funded at approximate $29.4 billion in FY 2013, resulting in an overall decrease from the FY 2012 funding level.    

"Without sufficient funding for the NIH and other federal agencies, research studies to find the causes of lupus and discover new, more tolerable and effective treatments for lupus will be delayed, and the search for cures will be seriously impaired.  Lupus research remains underfunded relative to the disease's scope and devastation.  

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 16,472.37 +200.36 1.23%
S&P 500 1,951.36 +27.54 1.43%
NASDAQ 4,707.7750 +80.6910 1.74%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs